Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | March 04, 2025 | March 07, 2025 |
| GeneDx Holdings Corp.SMFR · Entity 1634 | Director | October 15, 2022 | October 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date March 04, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,690 |
Reported balance
After 2025-03-04 transaction · row 1
1 source rowRow 1 · 2025-03-04 · Grant · Acquired 15,394 · Balance 69,690 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.12 · Expires 2035-03-04 | Direct | 23,726 |
Reported balance
After 2025-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-04 · Grant · Acquired 23,726 · Balance 23,726 F1: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.
GeneDx Holdings Corp.
Report date October 15, 2022 · Filed October 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 17,114 |
Reported balance
After 2022-10-15 transaction · row 1
1 source rowRow 1 · 2022-10-15 · Exercise / conversion · Acquired 4,278 · Balance 17,114 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,558 |
Reported balance
After 2022-10-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-15 · Exercise / conversion · Disposed 4,278 · Balance 8,558 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Other · Disposed 103,711 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2022-01-10 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-31 · Other · Disposed 6,949 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: This stock option was granted on January 10, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2022-03-27 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-31 · Other · Disposed 30,548 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: This stock option was granted on March 27, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2023-03-07 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-31 · Other · Disposed 49,224 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5: This stock option was granted on March 7, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-21 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-31 · Other · Disposed 25,625 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F6: This stock option was granted on May 21, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: This stock option was granted on January 10, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F4: This stock option was granted on March 27, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F5: This stock option was granted on March 7, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F6: This stock option was granted on May 21, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 26,834 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy The Pellini Family Trust | 0 |
Reported balance
After 2025-02-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 324,388 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-21 · Disposition to issuer · Disposed 916 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-21 · Disposition to issuer · Disposed 2,083 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-21 · Disposition to issuer · Disposed 3,333 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-21 · Disposition to issuer · Disposed 3,333 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
F2: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares.
F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,726 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004807 · form4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,726 Underlying: Common Stock · 23,726 shares Expires 2035-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004807 · form4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,690 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,333 | $8.84 Strike: $11.16 | $29,463.72 |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · derivative · entry 6 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2034-05-29 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $31.80 | $0.00 |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · derivative · entry 5 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2033-05-25 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,083 | $0.00 Strike: $85.80 | $0.00 |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · derivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2032-05-26 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 916 | $0.00 Strike: $672.90 | $0.00 |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 916 shares Expires 2031-05-05 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerCommon Stock | 324,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Pellini Family Trust Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2 · ownership.nature: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:07 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerCommon Stock | 26,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-027099 · ownership.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000950170-24-067529 · ownership.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:46 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 48,044 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005775 · form4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,044 Underlying: Common Stock · 48,044 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:46 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 31,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005775 · form4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,296 Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:04 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-032603 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2024 Stockholder Annual Meeting or May 25, 2024. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,329 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006337 · form4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,329 Underlying: Common Stock · 23,329 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006337 · form4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,968 Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 22:37 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054001 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,558 Underlying: Class A Common Stock · 4,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 22:37 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 4,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-054001 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · derivative · entry 8 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,271 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · derivative · entry 7 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,271 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,668 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · derivative · entry 6 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,668 shares Expires 2027-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GiftCommon Stock | 154,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · nonDerivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,289 F1 · kind: Immediately upon exercise of the Reporting Person's options, the Reporting Person transferred his shares as a gift to The Pellini Family Trust. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionCommon Stock | 60,000 | $0.63 | $37,800.00 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · nonDerivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionCommon Stock | 34,271 | $0.24 | $8,053.69 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 7, 2022 07:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionCommon Stock | 60,668 | $0.21 | $12,788.81 |
DisclosureSEC source: 0001209191-22-034752 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:04 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001209191-22-033019 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-05-26 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2023 Stockholder Annual Meeting or May 26, 2023. Read SEC document |
| May 18, 2022 Filed May 19, 2022 17:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | PurchaseCommon Stock | 26,834 | $3.30 | $88,552.20 |
DisclosureSEC source: 0001209191-22-030584 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,289 Read SEC document |
| May 02, 2022 Filed May 5, 2022 00:33 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 45,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027290 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,454 Underlying: Class A Common Stock · 45,454 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F1 · derivative.expiration_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| May 02, 2022 Filed May 5, 2022 00:33 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantStock Option (Right to Buy) · Derivative | 78,914 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001209191-22-027290 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| May 02, 2022 Filed May 6, 2022 23:04 UTC Amendment | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantStock Option · Derivative | 78,914 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-22-027693 · doc4a.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_price: This Form 4 amendment has been filed solely to correct the exercise price of a previously issued stock option to purchase shares of Class A Common Stock of the Issuer reported in a Form 4 filed on May 4, 2022 (the "Form 4"). The exercise price was inadvertently stated as $2.155 in the Form 4. The exercise price should have been stated as $2.20 in the Form 4. F2 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| April 27, 2022 Filed May 13, 2022 00:24 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028693 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. Read SEC document |
| April 27, 2022 Filed May 13, 2022 00:24 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 12,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028693 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| February 10, 2022 Filed Feb 1, 2023 18:49 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GiftCommon Stock | 72,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005999 · doc5.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,834 F1 · kind: This transaction represents the gift of shares by the Reporting Person to The Pellini Family Trust. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005499 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005499 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-061029 · doc4.xml · derivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-061029 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. F1 · derivative.expiration_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,286 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001209191-21-061029 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 Underlying: Class A Common Stock · 22,286 shares Expires 2031-10-14 F2 · derivative.exercise_date: The stock option shall vest as of 1/36 of the total shares monthly beginning on November 15, 2021 until fully vested, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,286 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001209191-21-061029 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 Underlying: Class A Common Stock · 22,286 shares Expires 2031-10-14 F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document |
| May 20, 2021 Filed Jun 1, 2021 21:45 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | ConversionSeries A Preferred Stock · Derivative | 96,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037021 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Pellini Family Trust Disclosed balance after: 0 Underlying: Common Stock · 96,944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of the Series A Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of the Series A Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of the Series A Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of the Series A Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares. Read SEC document |
| May 20, 2021 Filed Jun 1, 2021 21:45 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | ConversionCommon Stock | 96,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037021 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Pellini Family Trust Disclosed balance after: 96,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of the Series A Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 20,000 | $57.80 | $1,156,000.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 20,000 | $57.80 | $1,156,000.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011546 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011546 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-065102 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,000 | $60.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-20-065102 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 25,000 | $6.55 | $163,750.00 |
DisclosureSEC source: 0001209191-20-065102 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.